Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • IDweek2023 | A Comprehensive Review of Outcomes in Intravenous to Oral Antimicrobial Therapy in Uncomplicated β-hemolytic Streptococcus Bloodstream Infections in Immunocompromised Individuals

    IDweek2023 A Comprehensive Review of Outcomes in Intravenous to Oral Antimicrobial Therapy in Uncomplicated β-hemolytic Streptococcus Bloodstream Infections in Immunocompromised Individuals IDweek2023 A Comprehensive Review of Outcomes in Intravenous to Oral Antimicrobial Therapy in Uncomplicated β-hemolytic Streptococcus Bloodstream Infections in Immunocompromised Individuals

    2023.10.27
  • IDweek2023 | A Comprehensive Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) versus Dolutegravir/Lamivudine (DTG/3TC) in HIV Treatment

    IDweek2023 A Comprehensive Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) versus Dolutegravir/Lamivudine (DTG/3TC) in HIV Treatment In the relentless battle against HIV, the advent of antiretroviral therapy (ART) has marked a significant turning point. The development and introduction of drug regimens have revolutionized HIV treatment, transforming HIV from a fatal illness into a manageable chronic condition. However,…

    2023.10.27
  • IDweek2023 | The Revolutionary Shift in HIV Management: An In-Depth Analysis of Cabotegravir + Rilpivirine Long-Acting Treatment Versus Traditional Oral Antiretroviral Therapy

    IDweek2023 The Revolutionary Shift in HIV Management: An In-Depth Analysis of Cabotegravir + Rilpivirine Long-Acting Treatment Versus Traditional Oral Antiretroviral Therapy In the ever-evolving world of medicine, the ultimate goal has consistently been to enhance patient adherence and improve treatment outcomes. This is particularly apparent in the management of HIV, where antiretroviral therapy (ART) has…

    2023.10.27
  • IDweek2023 | Exploring the Consequences of Low-Level Viremia Among Women with HIV

    IDweek2023 Exploring the Consequences of Low-Level Viremia Among Women with HIV Understanding the dynamics of HIV infection is critical for managing and controlling the disease. A vital aspect of this understanding is the awareness of Low-Level Viremia (LLV), a condition experienced by about a third of people living with HIV. Despite its prevalence, there is…

    2023.10.27
  • IDweek2023 | Hepatitis B Reactivation in HIV Patients: A Comprehensive Study of Antiretroviral Therapy’s Role

    IDweek2023 Hepatitis B Reactivation in HIV Patients: A Comprehensive Study of Antiretroviral Therapy’s Role Hepatitis B, a viral infection that primarily affects the liver, can lead to serious complications, such as cirrhosis and hepatocellular carcinoma. In individuals living with HIV, the situation is further complicated since they face the risk of Hepatitis B reactivation -…

    2023.10.27
  • IDweek2023 | A Comprehensive Exploration of At-Home vs. In-Clinic Administration of Cabotegravir and Rilpivirine Long-Acting: An In-depth Analysis of an Implementation Science Trial

    IDweek2023A Comprehensive Exploration of At-Home vs. In-Clinic Administration of Cabotegravir and Rilpivirine Long-Acting: An In-depth Analysis of an Implementation Science Trial The approval of the long-acting injectable cabotegravir-rilpivirine in January 2021 marked a significant milestone in the medical realm. This dual-drug regimen has revolutionized the approach to HIV treatment by providing an effective and convenient…

    2023.10.27
  • IDweek2023 | A Deep Dive into the Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Insights from the OPERA® Cohort.

    IDweek2023 A Deep Dive into the Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Insights from the OPERA® Cohort. The world of HIV (Human Immunodeficiency Virus) management has seen remarkable strides over the years, with the advent of antiretroviral therapy (ART) significantly improving the quality of…

    2023.10.27
  • IDweek2023 | Understanding Post-Acute Sequelae of SARS-CoV-2 Infection: A Comprehensive Overview

    IDweek2023 Understanding Post-Acute Sequelae of SARS-CoV-2 Infection: A Comprehensive Overview The COVID-19 pandemic caused by the SARS-CoV-2 virus has had a significant impact on global health. While much attention has been given to the acute phase of the infection, there is emerging recognition of a subset of individuals experiencing persistent symptoms beyond the acute stage,…

    2023.10.27
«previous next»
Recent Posts
  • The Lancet Haematology | Professor Yanmin Zhao, Professor He Huang, and Professor Jimin Shi: Moving Low-Dose Ruxolitinib Upfront to GVHD Prophylaxis Significantly Reduces the Risk of Acute GVHD After Haploidentical Transplantation
  • Prof. Cai Zhen: Challenges and Advances in the Treatment of Extramedullary Disease in Multiple Myeloma | 2026 Cross-Strait Hematology Conference
  • Prof. Wang Liang: How to Precisely Choose Between Autologous and Allogeneic Transplantation for First-Line Consolidation in Peripheral T-Cell Lymphoma? | 2026 Cross-Strait Hematology Conference
  • Professor Huang He: Advances in Novel Cellular Immunotherapy and Clinical Translation丨2026 Cross-Strait Hematology Academic Conference
  • CACA GU丨Yiping Zhu: Advancing Standardized, Whole-Course Bladder Cancer Management—from First-Line Treatment Innovation to Multidisciplinary Collaboration
Recent Comments
    Archives
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top